Oct 3, 2024 4:15 pm EDT BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Sep 19, 2024 6:55 am EDT BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
Aug 13, 2024 4:05 pm EDT BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 6, 2024 4:05 pm EDT BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
Jul 23, 2024 7:10 am EDT BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
Jun 27, 2024 7:40 am EDT BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
Jun 17, 2024 7:05 am EDT BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
Jun 13, 2024 7:00 am EDT BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
Jun 4, 2024 8:50 am EDT BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference